What happened
Shares of Insulet (NASDAQ: PODD) were skyrocketing 16.6% higher as of 10:40 a.m. ET on Friday. The big gain came after the insulin pump maker announced its third-quarter results following the market close on Thursday.
Insulet reported Q3 revenue of $340.8 million, a 23.7% year-over-year jump. On a constant-currency basis, the company's revenue increased by 28.5% from the prior-year period. This was well above Insulet's guidance of 17% to 20% revenue growth on a constant-currency basis.
The company posted a net loss of $5.2 million, or $0.08 per share, in the third quarter, based on generally accepted accounting principles (GAAP). However, Insulet recorded non-GAAP adjusted net income of $31.6 million, or $0.45 per share. This result blew past the consensus Wall Street adjusted earnings estimate of $0.15 per share.
Insulet also raised its full-year 2022 revenue guidance. The company now projects revenue growth of between 18% and 19%, up from its previous outlook of 14% to 17% growth.
So what
The U.S. launch of the company's Omnipod 5 insulin pump is going very well. Insulet CEO Jim Hollingshead said that the adoption of the device "is exceeding our expectations and proving to be the game-changer we knew it would be."
Investors shouldn't get too excited about one positive quarter. After all, a company's quarterly results represent only a snapshot of its performance. On the other hand, enthusiasm is warranted when strong results in a quarter are indicative of a broader trend. That appears to be the case with Insulet.
Now what
With Insulet recently winning CE mark approval for Omnipad 5 in Europe, look for international sales growth to accelerate. The stock should be in a good position to continue its momentum next year.
10 stocks we like better than Insulet
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Insulet wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of September 30, 2022
Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
